{"id":"W2017218408","doi":"10.1097/cad.0b013e328011fd99","title":"An open-label, multicenter phase II trial of capecitabine in patients with cisplatin-refractory or relapsed germ cell tumors","year":2007,"lang":"en","type":"article","venue":"Anti-Cancer Drugs","topic":"Testicular diseases and treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Capecitabine; Medicine; Neutropenia; Tolerability; Internal medicine; Chemotherapy; Gastroenterology; Cisplatin; Transplantation; Refractory (planetary science); Germ cell tumors; Surgery; Progressive disease; Multicenter trial; Oncology; Adverse effect; Cancer; Randomized controlled trial; Multicenter study","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002058186,0.001763879,0.002149186,0.000481852,0.0005473765,0.0008060479,0.0008289215,0.001249282,0.00263163],"category_scores_gemma":[0.001727561,0.000540744,0.0008486822,0.0004071324,0.001001739,0.0009632766,0.0003610961,0.002994773,0.0004941033],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007379506,"about_ca_system_score_gemma":0.001076196,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005306269,"about_ca_topic_score_gemma":0.001858298,"domain_scores_codex":[0.9993721,0.0003922375,0.0000297336,0.0000808099,0.00004038497,0.00008479674],"domain_scores_gemma":[0.998957,0.0002228219,0.0002214333,0.00007546608,0.00005647369,0.0004668916],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8003589,0.07071261,0.006287158,0.0008422898,0.0008490004,0.000491025,0.0003712313,0.00194865,0.02887223,0.0003818622,0.002924845,0.08596022],"study_design_scores_gemma":[0.7109127,0.2815509,0.004079143,0.00002405981,0.00011827,0.0001693737,0.00003026988,0.0006869274,0.0012063,0.0001049162,0.001102346,0.00001464018],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9916995,0.002807708,0.0005866601,0.000485363,0.0001678871,0.003008488,0.0003892022,0.00005030818,0.0008049819],"genre_scores_gemma":[0.9874247,0.001915629,0.002408848,0.0008359334,0.0002938494,0.004121966,0.001386742,0.00002181552,0.001590598],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00263163,"threshold_uncertainty_score":0.01088488,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01958008612328598,"score_gpt":0.3350720642321228,"score_spread":0.3154919781088368,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}